Spinal Cord Stimulation Combined With Brain-Computer Interface Rehabilitation to Improve Motor Function After Stroke (SCS-BCI Rehab)

November 10, 2026 updated by: Qingdao Central Hospital

A Study on the Efficacy Evaluation of Spinal Cord Stimulation Combined With a Brain-Computer Interface for Improving Motor Function in Patients With Post-Stroke Hemiplegia Based on Multi-Source Neurophysiological Data

This study evaluates the effects of spinal cord stimulation (SCS) combined with brain-computer interface (BCI)-assisted rehabilitation on motor function in patients with post-stroke hemiplegia using multisource neurophysiological data. In this single-group study with repeated measurements, participants undergo four weeks of SCS combined with BCI-driven upper- and lower-limb rehabilitation. Immediate motor performance is compared between SCS ON and OFF conditions under standardized tasks. Changes in motor function and multisource neurophysiological and kinematic measures are also assessed before and after rehabilitation to characterize treatment responses and explore their relationships with clinical motor improvement.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This is a single-group study using a within-participant pre-post design with repeated measurements. The study enrolls patients with post-stroke hemiplegia who meet the clinical indications for spinal cord stimulation (SCS) surgery and require SCS treatment. Following preoperative baseline assessment, participants undergo SCS implantation based on clinical indications, followed by stimulation parameter adjustment, individualized brain-computer interface (BCI) model calibration, and rehabilitation device setup.

The study includes four weeks of SCS combined with BCI-assisted synchronized upper- and lower-limb active rehabilitation. The first week includes postoperative recovery, stimulation parameter adjustment, and early closed-loop training. During rehabilitation, the BCI system identifies motor intentions from electroencephalography (EEG) signals in real time and drives upper- and lower-limb rehabilitation robots to provide corresponding assisted movements, establishing a closed-loop process integrating motor intention, robotic assistance, and sensorimotor feedback. Training is planned for three to five sessions per week, with 45-60 minutes of effective training per session.

Repeated measurements under SCS ON and OFF conditions are performed to evaluate the immediate effects of stimulation. With BCI closed-loop tasks, robotic assistance settings, and movement requirements held constant, motor performance during affected upper-limb, lower-limb, and synchronized upper- and lower-limb tasks is compared between SCS OFF and ON conditions. At least one standardized ON/OFF comparison is conducted each week during the intervention period.

Assessments are conducted at the preoperative baseline (T0), postoperative immediate-effect assessment (T1), week-2 mid-intervention assessment (T2), week-4 endpoint assessment (T3), and follow-up (T4). Clinical motor function assessments and multisource data, including EEG, functional near-infrared spectroscopy, electromyography, electrodermal activity, upper- and lower-limb kinematics, and BCI control logs, are used to evaluate changes in motor function, cortical activity, muscle activation patterns, interlimb coordination, and BCI closed-loop performance. Relationships between objective measures and improvements in clinical motor function are also examined.

Study Type

Observational

Enrollment (Estimated)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Shandong
      • Qingdao, Shandong, China, 266033
        • Recruiting
        • Qingdao Central Hospital, University of Health and Rehabilitation Sciences
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The study population consists of adults aged 18 to 75 years with imaging-confirmed ischemic or hemorrhagic stroke and unilateral hemiplegia. Participants must meet the clinical indications for spinal cord stimulation (SCS) implantation and be scheduled to undergo SCS surgery for clinical reasons. They must be clinically stable and able to complete brain-computer interface (BCI) calibration, synchronized upper- and lower-limb rehabilitation assessments, and multisource physiological data collection

Description

Inclusion Criteria

  1. Age 18-75 years.
  2. Patients who meet the clinical indications for SCS surgery, require SCS to improve their condition, and plan to undergo the procedure at the study center.
  3. Ischemic or hemorrhagic stroke confirmed by CT or MRI.
  4. Unilateral hemiplegia with assessable motor dysfunction in both the affected upper and lower limbs.
  5. Stable clinical condition and ability to cooperate with SCS implantation surgery, BCI calibration, synchronized upper- and lower-limb robotic rehabilitation, and collection of all multisource physiological data.
  6. Adequate cognitive and comprehension abilities to complete motor imagery or motor-attempt tasks and meet the requirements for BCI modeling and closed-loop control.
  7. Meets the clinical indications for epidural SCS implantation based on neurosurgical evaluation.
  8. Body size, joint range of motion, and tolerance of sitting or standing are compatible with the safe use of upper- and lower-limb rehabilitation robots.
  9. Written informed consent signed by the patient or their legally authorized representative.

Exclusion Criteria

  1. Severe cognitive impairment, complete aphasia, or severe unilateral spatial neglect that prevents completion of all study tasks.
  2. Uncontrolled epilepsy or frequent seizures during the previous three months.
  3. Contraindications to surgery or anesthesia, including severe cardiopulmonary disease, coagulation disorders, or active systemic infection.
  4. Implanted electronic medical devices with electromagnetic compatibility conflicts involving the SCS system, EEG/fNIRS brain recording devices, or rehabilitation robots.
  5. Severe limb contracture, persistent severe pain, structural joint injury, or positional intolerance that prevents standardized synchronized rehabilitation training.
  6. Skin lesions or skin disorders on the head or limbs that prevent the use of EEG, fNIRS, EMG, or electrodermal sensors.
  7. Any other condition judged by the investigator to make participation in the study inappropriate.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
SCS Combined With BCI-Assisted Synchronized Upper- and Lower-Limb Active Rehabilitation

All participants receive SCS combined with EEG-driven BCI-assisted synchronized upper- and lower-limb active rehabilitation. After baseline assessment, SCS implantation, and parameter adjustment, participants complete four weeks of training and weekly SCS ON/OFF comparisons under consistent BCI tasks and robotic assistance settings. Clinical motor outcomes, multisource neurophysiological signals, kinematics, and BCI control logs are collected

An epidural SCS system is used, comprising stimulation electrodes, a pulse generator or external stimulator, a programming system, and an event recording system. The clinical team determines the stimulation target according to motor impairments, surgical safety, and the established treatment plan. Standardized SCS OFF and ON comparisons are performed under consistent BCI tasks and robotic assistance settings, with stimulation parameters, motor performance, and related physiological data recorded

The BCI active rehabilitation system identifies motor intention during imagery or attempted movement from real-time EEG signals and triggers corresponding assisted movements using upper- and lower-limb rehabilitation robots, forming a closed loop between motor intention, sensory feedback, and limb movement. Rehabilitation continues for four weeks, three to five times per week (preferably five), with 45-60 minutes of effective training per session. At least one standardized SCS ON/OFF comparison is performed weekly

Other Names:
  • EEG-Driven BCI-Assisted Synchronized Upper- and Lower-Limb Active Rehabilitation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference in Immediate Motor Task Performance Between SCS ON and OFF Conditions
Time Frame: Intervention weeks 1-4 (T1-T3)

Motor performance during affected upper-limb, lower-limb, and synchronized upper- and lower-limb tasks is compared between SCS ON and OFF conditions, with BCI closed-loop mode and robotic assistance parameters kept consistent, to evaluate the immediate effects of SCS

Intervention weeks 1-4 (T1-T3)
Change in Upper- and Lower-Extremity Fugl-Meyer Assessment Scores
Time Frame: Preoperative baseline (T0, 1-2 weeks before surgery) to the end of intervention week 4 (T3)

The Fugl-Meyer Assessment (FMA) is used to evaluate changes in upper- and lower-extremity motor function separately before and after four weeks of combined rehabilitation

Preoperative baseline (T0, 1-2 weeks before surgery) to the end of intervention week 4 (T3)
Pearson/Spearman Correlation Between Multisource Objective Measures and Clinical Motor Improvement
Time Frame: Preoperative baseline (T0, 1-2 weeks before surgery) to the end of intervention week 4 (T3)

Pearson or Spearman correlation analysis will be performed to examine the correlation between multisource neurophysiological measures (EEG, fNIRS, EMG, electrodermal), kinematic parameters, and BCI closed-loop performance metrics, and the change in Fugl-Meyer Assessment (FMA) score, to identify objective features linked to the effects of combined rehabilitation.

Preoperative baseline (T0, 1-2 weeks before surgery) to the end of intervention week 4 (T3)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in 10-Meter Walk Test Speed
Time Frame: T0 (1-2 weeks before surgery), T3 (end of intervention week 4), and T4 (4 weeks after SCS electrode removal)

Walking ability is assessed using the 10-Meter Walk Test.

T0 (1-2 weeks before surgery), T3 (end of intervention week 4), and T4 (4 weeks after SCS electrode removal)
Change in Modified Ashworth Scale Scores
Time Frame: T0 (1-2 weeks before surgery), T3 (end of intervention week 4), and T4 (4 weeks after SCS electrode removal)

Changes in spasticity of the affected upper and lower limbs are assessed using the Modified Ashworth Scale

T0 (1-2 weeks before surgery), T3 (end of intervention week 4), and T4 (4 weeks after SCS electrode removal)
Changes in Motor-Related EEG Features
Time Frame: T0 (1-2 weeks before surgery) to T4 (4 weeks after SCS electrode removal), with assessments at 1 week post-surgery (T1), end of intervention week 2 (T2), end of intervention week 4 (T3).

Changes in movement-related EEG rhythms, movement-related cortical potentials, and motor intention decoding features are assessed

T0 (1-2 weeks before surgery) to T4 (4 weeks after SCS electrode removal), with assessments at 1 week post-surgery (T1), end of intervention week 2 (T2), end of intervention week 4 (T3).
Changes in Motor-Area fNIRS Hemodynamic Responses
Time Frame: T0 (1-2 weeks before surgery) to T4 (4 weeks after SCS electrode removal), with assessments at 1 week post-surgery (T1), end of intervention week 2 (T2), end of intervention week 4 (T3).

Changes in motor-area hemodynamic responses during motor tasks are assessed using functional near-infrared spectroscopy (fNIRS)

T0 (1-2 weeks before surgery) to T4 (4 weeks after SCS electrode removal), with assessments at 1 week post-surgery (T1), end of intervention week 2 (T2), end of intervention week 4 (T3).
Changes in Upper- and Lower-Limb EMG Activity and Muscle Synergies
Time Frame: T0 (1-2 weeks before surgery) to T4 (4 weeks after SCS electrode removal), with assessments at 1 week post-surgery (T1), end of intervention week 2 (T2), end of intervention week 4 (T3).

Changes in target-muscle activation, active contribution, abnormal muscle synergies, co-contraction, and interlimb temporal coupling are assessed using upper- and lower-limb electromyography (EMG)

T0 (1-2 weeks before surgery) to T4 (4 weeks after SCS electrode removal), with assessments at 1 week post-surgery (T1), end of intervention week 2 (T2), end of intervention week 4 (T3).
Changes in Electrodermal Responses and Stimulation Tolerability
Time Frame: T0 (1-2 weeks before surgery) to T4 (4 weeks after SCS electrode removal), including assessments during the 4-week intervention period

Electrodermal responses and stimulation tolerability are evaluated using electrodermal signals and records of stimulation-related discomfort

T0 (1-2 weeks before surgery) to T4 (4 weeks after SCS electrode removal), including assessments during the 4-week intervention period
Changes in Upper- and Lower-Limb Kinematics and Coordination
Time Frame: T0 (1-2 weeks before surgery) to T4 (4 weeks after SCS electrode removal), with assessments at 1 week post-surgery (T1), end of intervention week 2 (T2), end of intervention week 4 (T3).

Changes in movement speed, smoothness, trajectory deviation, joint range of motion, gait or pedaling symmetry, and interlimb coordination are assessed

T0 (1-2 weeks before surgery) to T4 (4 weeks after SCS electrode removal), with assessments at 1 week post-surgery (T1), end of intervention week 2 (T2), end of intervention week 4 (T3).
BCI Decoding and Closed-Loop Control Performance
Time Frame: From initial BCI calibration (T0, 1-2 weeks before surgery) to end of intervention week 4 (T3), with follow-up assessment at T4 (4 weeks after SCS electrode removal)

BCI performance is evaluated using decoding accuracy, valid trigger rate, false trigger rate, control latency, robotic task completion rate, assistance level, and online model stability

From initial BCI calibration (T0, 1-2 weeks before surgery) to end of intervention week 4 (T3), with follow-up assessment at T4 (4 weeks after SCS electrode removal)
Safety, Training Completion, and Data Acquisition Quality
Time Frame: During the 4-week intervention after SCS implantation, with final assessment at T4 (4 weeks after SCS electrode removal)

SCS-, BCI-, and robotic device-related adverse events, training completion, device tolerability, and the completeness and quality of synchronized upper- and lower-limb data acquisition are recorded

During the 4-week intervention after SCS implantation, with final assessment at T4 (4 weeks after SCS electrode removal)
Change in Berg Balance Scale Score
Time Frame: T0 (1-2 weeks before surgery), T3 (end of intervention week 4), and T4 (4 weeks after SCS electrode removal)

Balance function is assessed using the Berg Balance Scale.

T0 (1-2 weeks before surgery), T3 (end of intervention week 4), and T4 (4 weeks after SCS electrode removal)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Feng Jin, MD, Qingdao Central Hospital, University of Health and Rehabilitation Sciences

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 21, 2026

Primary Completion (Estimated)

September 30, 2027

Study Completion (Estimated)

March 31, 2028

Study Registration Dates

First Submitted

October 22, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared with external researchers. Study data will be used for analyses within this research project. Study findings will be reported in aggregate form while protecting participant privacy

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.